← Back to Search
Management Of Immune-related Adverse Events And Kinetics Of Response With Ipilimumab.
J. Weber, K. Kähler, A. Hauschild
Published 2012 · Medicine
Download PDFAnalyze on Scholarcy
Monoclonal antibodies directed against the immune checkpoint protein cytotoxic T-lymphocyte antigen-4 (CTLA-4; CD152)-ipilimumab and tremelimumab-have been investigated in metastatic melanoma and other cancers and have shown promising results. Recently, ipilimumab was approved by the US Food and Drug Administration for the treatment of metastatic melanoma. We review the literature on managing the adverse effects and kinetics of tumor regression with ipilimumab and provide guidelines on their management. During treatment with these antibodies, a unique set of adverse effects may occur, called immune-related adverse events (irAEs). These include rashes, which may rarely progress to life-threatening toxic epidermal necrolysis, and colitis, characterized by a mild to moderate, but occasionally also severe and persistent diarrhea. Hypophysitis, hepatitis, pancreatitis, iridocyclitis, lymphadenopathy, neuropathies, and nephritis have also been reported with ipilimumab. Early recognition of irAEs and initiation of treatment are critical to reduce the risk of sequelae. Interestingly, irAEs correlated with treatment response in some studies. Unique kinetics of response have been observed with CTLA-4 blockade with at least four patterns: (1) response in baseline lesions by week 12, with no new lesions seen; (2) stable disease, followed by a slow, steady decline in total tumor burden; (3) regression of tumor after initial increase in total tumor burden; and (4) reduction in total tumor burden during or after the appearance of new lesion(s) after week 12. We provide a detailed description of irAEs and recommendations for practicing oncologists who are managing them, along with the unusual kinetics of response associated with ipilimumab therapy.
This paper references
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy.
J. Yuan (2010)
The B7 family revisited.
R. Greenwald (2005)
Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma
O. Hamid (2007)
Patient Responses to Ipilimumab, a Novel Immunopotentiator for Metastatic Melanoma: How Different are these From Conventional Treatment Responses?
G. Pennock (2012)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
J. Weber (2009)
Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.
J. Blansfield (2005)
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
F. S. Hodi (2003)
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.
K. Peggs (2006)
Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis.
M. Robinson (2004)
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.
J. Wolchok (2010)
CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
P. A. Prieto (2012)
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
P. Attia (2005)
Phase I/II trial of tremelimumab in patients with metastatic melanoma.
L. Camacho (2009)
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.
E. Tivol (1995)
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.
Kimberly E. Beck (2006)
Phase II trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with a multi-peptide vaccine for resected stages IIIC and IV melanoma.
J. Weber (2006)
Association between immune-related adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials.
J. Lutzky (2009)
Cytotoxic T-Lymphocyte-Associated Antigen 4 Antibody-Induced Colitis and Its Management with Infliximab
R. Johnston (2008)
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
P. Waterhouse (1995)
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
G. Phan (2003)
The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases.
Y. Saenger (2008)
Effect of ipilimumab at 10 mg/kg on disease control in patients (pts) with M1c-stage melanoma in relation to baseline lactate dehydrogenase (LDH) levels.
M. Smylie (2009)
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.
S. O’Day (2010)
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.
Sara Redaelli (2009)
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
C. Robert (2011)
Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report.
S. Bhatia (2009)
Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
A. Hoos (2010)
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases
A. D. Giacomo (2008)
Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma
A. Ribas (2008)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
J. Wolchok (2009)
Anti-CTLA4 Monoclonal Antibody Induced Sarcoidosis in a Metastatic Melanoma Patient
A. Eckert (2008)
Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade
Stephanie G Downey (2007)
This paper is referenced by
Ryan J. Sullivan (2013)
Immune‐related adverse reactions in the hepatobiliary system: second‐generation check‐point inhibitors highlight diverse histological changes
Y. Zen (2019)
Cancer-treatment-induced neurotoxicity—focus on newer treatments
Jacqueline B Stone (2016)
T. Tokudome (2016)
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.
S. Champiat (2016)
Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies
V. Sibaud (2016)
Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan
A. Shimomura (2017)
Central nervous system toxicities of anti-cancer immune checkpoint blockade
Jonathan T. Blackmon (2016)
Hypophysite induite par les anticorps monoclonaux anti-CTLA-4
Jaafar Jaafar (2019)
Expert opinion on pituitary complications in immunotherapy Opinion d ’ expert sur les complications hypophysaires de l ’ immunothérapie
Claire Brieta (2018)
Hepatotoxicity of New Antitumor Agents
Nelia Hernández (2017)
Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer
Yukihiro Toi (2018)
Management of the cutaneous adverse effects of antimelanoma therapy.
R. Liu (2017)
Immune Checkpoint Inhibitor Therapy Associated Hypophysitis
Moeber Mahzari (2015)
Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center
D. Johnson (2015)
Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer.
M. Howell (2015)
The role of immunosuppressive agents in the management of severe and refractory immune‐related adverse events
A. Wang (2020)
CMV coinfection in treatment refractory immune checkpoint inhibitor colitis
Kevin B Harris (2020)
Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective
C. Quinn (2020)
Systemic inflammatory response and nutritional biomarkers as predictors of nivolumab efficacy for gastric cancer
T. Namikawa (2020)
Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report
A. Takeno (2019)
Foreign body reaction triggered by CTLA-4 blockade 25 years after dermal filler injection , a case report
C. Bisschop ()
Immune modulation in cancer with antibodies.
D. Page (2014)
Noninvasive Imaging of Cancer Immunotherapy
Omar Abousaway (2020)
Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
Morganna Freeman-Keller (2015)
Anomalies pigmentaires induites par les traitements anticancéreux. Deuxième partie : les thérapies ciblées
V. Sibaud (2013)
Clinical Ophthalmic Oncology
A. Singh (2019)
Kinetics of Appearance of Immune-Related Adverse Events
M. Postow (2015)
Current State of Immune-Based Therapies for Glioblastoma.
M. Lim (2016)
Ipilimumab-associated halo-like inflammatory reactions around nevi during therapy for metastatic melanoma.
Dema T. Alniemi (2018)
Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities
S. Cousin (2016)
Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients—Literature Review
M. Dudzińska (2020)See more